Inside the Clinic: Myeloproliferative Neoplasms: Current and Future Standards of Care

Experts share insight on the evolving treatment armamentarium for myeloproliferative neoplasms.

EP. 11: Use of Ruxolitinib in Myelofibrosis

June 2nd 2022

Expert perspectives on the role of ruxolitinib in patients who require systemic therapy for myelofibrosis.

EP. 12: Myelofibrosis: Use of Fedratinib and Pacritinib Therapy

June 2nd 2022

Shared insight on the respective roles of fedratinib and pacritinib in patients diagnosed with myelofibrosis.

EP. 13: Selection and Management of JAK Inhibitor Therapy in MF

June 9th 2022

Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.

EP. 14: Myelofibrosis: Patient Monitoring and Triggers to Change Therapy

June 9th 2022

Expert perspectives on monitoring patients receiving therapy for myelofibrosis, with additional considerations for when it is appropriate to switch therapy.

EP. 15: Novel Agents in the Pipeline for Myelofibrosis

June 16th 2022

A comprehensive review of novel agents currently under investigation with a potential role in the myelofibrosis treatment landscape.

EP. 16: Myelofibrosis: Novel Combination Strategies

June 16th 2022

Focusing on novel combination strategies, experts review clinical trial data and consider where these regimens may fall in the myelofibrosis treatment armamentarium.

EP. 17: Clinical Pearls for the Management of Myelofibrosis

June 23rd 2022

Closing out their discussion on myelofibrosis, experts provide practical advice for identifying and managing patients in real-world practice.